ArticlePloS one2025
Eosinopenia as a predictor of clinical outcomes in hospitalized patients with community-acquired pneumonia: A retrospective cohort study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Eosinopenia has been reported as a predictor of unfavorable outcomes and a marker of severity in bacterial infections. We describe the association between eosinopenia and clinical outcomes in hospitalized patients with CAP. We conducted a retrospective study of hospitalized adult patients with community-acquired pneumonia at a large US academic medical center from January 2009 to December 2019. We collected data on patient demographics, disease severity, comorbidities, smoking history, inflammatory markers, blood eosinophil levels, mortality, length of hospital stay, and need for intensive care unit (ICU) or mechanical ventilation. According to blood eosinophil count, patients were grouped as eosinopenic (<50/μL) and non-eosinopenic (≥50/μL) based on prior studies. Analysis was performed using nonparametric Wilcoxon rank-sum test for continuous variables and the chi-square test for categorical variables. A logistic regression analysis with robust standard errors was used to assess the associations between eosinopenia and patient centered outcomes (in-hospital mortality, 30-day mortality, length of hospital stay, need for mechanical ventilation support, vasopressor support and ICU admission). Of the 3285 patients with CAP infection included in our analysis, 1304 (39.70%) were eosinopenic. Age, gender, race, and smoking status were similar between the two groups. The eosinopenic group had significantly higher inflammatory markers as measured by C-reactive protein (CRP), and higher disease severity scores., After adjusting for disease severity, chronic obstructive pulmonary (COPD), and CRP there was no significant difference in hospital mortality (odds ratio [OR] 2.16, 95% confidence interval [CI] 0.68-6.8), ICU admission (OR: 1.21, 95% CI: 0.83-1.79), invasive and non-invasive ventilatory support (OR: 1.21, 95% CI: 0.52-2.81). Contrary to previously published data, our analysis did not demonstrate an association between eosinopenia and increased mortality risk in hospitalized patients with CAP highlighting the complexity of CAP prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.